Boehringer Ingelheim announces Phase III nintedanib trial results in patients with metastatic colorectal cancer

Boehringer Ingelheim has announced that its   LUME-Colon 1 study has met   one of the co-primary endpoints of progression-free survival (PFS) in pre-treated patients with metastatic colorectal cancer (mCRC).

Source: Drug Development Technology - October 10, 2016 Category: Pharmaceuticals Source Type: news